Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
South Korea: These 50 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "South Korea: These 50 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can TYMLOS (abaloparatide) generic drug versions launch in South Korea?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: South Korea Patent 101,512,377
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in South Korea?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: South Korea Patent 20,090,083,350
Patent Title: 골 아나볼릭 단백질을 위한 약물 전달 방법 (METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN)
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in South Korea?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: South Korea Patent 20,150,020,289
Patent Title: METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in South Korea?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: South Korea Patent 20,170,067,906
Patent Title: 골 아나볼릭 단백질을 위한 약물 전달 방법 (METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN)
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in South Korea?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: South Korea Patent 20,180,117,738
Patent Title: 골 아나볼릭 단백질을 위한 약물 전달 방법 (METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN)
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in South Korea?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: South Korea Patent 101,341,792
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in South Korea?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: South Korea Patent 20,080,050,601
Patent Title: AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in South Korea?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: South Korea Patent 20,130,058,072
Patent Title: AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in South Korea?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: South Korea Patent 101,467,723
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. Additional details are available on the fedratinib hydrochloride profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in South Korea?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: South Korea Patent 101,494,468
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. Additional details are available on the fedratinib hydrochloride profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in South Korea?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: South Korea Patent 101,358,574
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in South Korea?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: South Korea Patent 20,080,065,662
Patent Title: NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in South Korea?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: South Korea Patent 101,432,821
See drug price trends for ENTRESTO SPRINKLE.
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in South Korea?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: South Korea Patent 101,549,318
See drug price trends for ENTRESTO SPRINKLE.
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: South Korea Patent 101,513,736
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: South Korea Patent 101,513,737
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: South Korea Patent 101,513,842
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: South Korea Patent 20,090,085,096
Patent Title: 합성 펩타이드 아마이드 (SYNTHETIC PEPTIDE AMIDES)
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: South Korea Patent 20,090,085,097
Patent Title: 합성 펩타이드 아마이드와 그의 다이머 (SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF)
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: South Korea Patent 20,140,056,396
Patent Title: 합성 펩타이드 아마이드와 그의 다이머 (SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF)
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in South Korea?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 101,608,755
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN
The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 101,405,545
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 101,415,329
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 20,120,107,533
Patent Title: GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 20,130,123,471
Patent Title: GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in South Korea?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: South Korea Patent 101,514,700
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in South Korea?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: South Korea Patent 20,090,087,020
Patent Title: （알파 Ｓ, 베타 Ｒ）―６―브로모―알파―［２―（디메틸아미노）에틸］―２―메톡시―알파―１―나프탈레닐―베타―페닐―３―퀴놀린에탄올의 푸마레이트 염 (FUMARATE SALT OF ALPHA S BETA R-6-BROMO-ALPHA-[2-DIMETHYLAMINOETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL)
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 101,174,201
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 101,364,277
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 20,090,087,127
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 20,100,050,557
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 20,110,117,195
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in South Korea?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: South Korea Patent 101,464,391
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in South Korea?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: South Korea Patent 20,090,087,916
Patent Title: 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in South Korea?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: South Korea Patent 101,451,993
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in South Korea?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: South Korea Patent 101,593,579
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in South Korea?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: South Korea Patent 20,140,088,617
Patent Title: THERAPEUTIC COMPOSITIONS
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in South Korea?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: South Korea Patent 101,436,303
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in South Korea?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Korea Patent 20,090,121,291
Patent Title: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in South Korea?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Korea Patent 101,486,091
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in South Korea?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Korea Patent 20,090,109,115
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can LEXISCAN (regadenoson) generic drug versions launch in South Korea?
Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 02, 2027
Generic Entry Controlled by: South Korea Patent 20,080,090,491
Patent Title: PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. Additional details are available on the regadenoson profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,670,016
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,837,010
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,122,254
Patent Title: 안정한 소화 효소 조성물 (Stable digestive enzyme compositions)
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 20,150,038,322
Patent Title: 안정한 소화 효소 조성물 (Stable digestive enzyme compositions)
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,670,016
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,837,010
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,122,254
Patent Title: 안정한 소화 효소 조성물 (Stable digestive enzyme compositions)
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 20,150,038,322
Patent Title: 안정한 소화 효소 조성물 (Stable digestive enzyme compositions)
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch in South Korea?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: South Korea Patent 101,495,146
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. Additional details are available on the amphetamine profile page.
When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in South Korea?
Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: South Korea Patent 101,495,146
TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug. There has been litigation on patents covering TUZISTRA XR
See drug price trends for TUZISTRA XR.
The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.
When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in South Korea?
Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: South Korea Patent 101,549,364
VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.
See drug price trends for VANFLYTA.
The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.
When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in South Korea?
Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: South Korea Patent 20,080,108,548
Patent Title: IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.
See drug price trends for VANFLYTA.
The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.
When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in South Korea?
Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: South Korea Patent 20,140,091,619
Patent Title: IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.
See drug price trends for VANFLYTA.
The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.
When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in South Korea?
Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,029,690
Patent Title: INTRANASAL ADMINISTRATION OF KETAMINE TO TREAT DEPRESSION
See drug price trends for SPRAVATO.
The generic ingredient in SPRAVATO is esketamine hydrochloride. Additional details are available on the esketamine hydrochloride profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in South Korea?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Korea Patent 101,478,593
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in South Korea?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,123,882
Patent Title: PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch in South Korea?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: South Korea Patent 20,080,106,564
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.
When can INLYTA (axitinib) generic drug versions launch in South Korea?
Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: South Korea Patent 101,237,588
INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.
When can INLYTA (axitinib) generic drug versions launch in South Korea?
Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: South Korea Patent 20,090,127,949
INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in South Korea?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: South Korea Patent 101,475,968
See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 101,475,971
PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 101,537,200
PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 20,100,020,456
PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 20,140,049,086
PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 20,150,008,513
PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in South Korea?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: South Korea Patent 101,441,365
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in South Korea?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: South Korea Patent 20,090,018,104
Patent Title: ACETYLENIC HETEROARYL COMPOUNDS
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in South Korea?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: South Korea Patent 101,668,973
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in South Korea?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: South Korea Patent 20,150,090,264
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Korea?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Korea Patent 101,930,588
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Korea?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Korea Patent 20,100,017,904
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Korea?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Korea Patent 20,160,002,937
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in South Korea?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: South Korea Patent 101,549,876
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in South Korea?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: South Korea Patent 20,100,049,010
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in South Korea?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: South Korea Patent 20,150,036,210
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in South Korea?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 101,486,228
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 101,598,402
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 101,916,024
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 102,061,001
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,100,031,512
Patent Title: SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,130,133,881
Patent Title: SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.